TRA2A and esophageal cancer: Investigating how RBMX influences alternative splicing and m6A methylation, particularly in relation to other RNA-binding proteins such as TRA2A, may reveal new insights into the biology of esophageal cancer and resistance to therapies like sorafenib (80).